Business intelligence
for the Lab Diagnostics industry
Already a Subscriber? Log in Here
We offer four monthly reports, each focused on the industry from a unique angle, covering science & technology, compliance, business, and legislation & regulations.
Diagnostic Testing & Emerging Technologies
Keeps you up-to-date on new diagnostic tests, testing trends and opportunities, and emerging test technologies
Lab Compliance Advisor
Offers practical, “what-to-do” and “how-to-do-it” help to comply with the latest state and federal laws, rules, and regulations that affect your diagnostic lab or pathology practice
Laboratory Industry Report
Keeps you up-to-date on lab business and competitive strategy, market trends and opportunities, and M&A and investment activity in today’s diagnostic lab industry
National Lab Reporter
Keeps you up-to-date on federal and state laws, regulations, new legislation, and court cases that affect your diagnostic lab or pathology practice
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
Weekly Enforcement Report: Drug Testing Fraud Dominates
Last week’s three key cases included two involving drug testing that was either medically unnecessary, or not provided at all.
Proposed Rule Would Water Down CLIA Requirements for Lab Directors and Testing Personnel
While the rule has not yet been approved, if it is, nursing degrees would be considered the equivalent of biological science degrees.
Quest Expands into MRD Liquid Biopsy with Haystack Oncology Buy
The acquisition of the Johns Hopkins spin out and its liquid biopsy ctDNA test will significantly strengthen Quest’s oncology offerings.
How Medicaid Redetermination Will Impact Your Patients and Your Bottom Line, and What to Do About It
Join us and our experts to learn how to navigate the Medicaid Redetermination process in this free webinar.
Three Strategies for Creating a Sustainable Recruiting Model
What should pathology groups and labs do in order to attract and maintain clinical talent in today’s economy?
M&A & Strategic Deals: Dealmaking Shows New Signs of Life but FTC Scrutiny Casts a Dark Shadow
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
June 2023 FDA Watch
So far, it appears many post-PHE COVID-19 tests will be panels for detecting and differentiating among multiple respiratory viruses.
DX Deals: Large Healthcare Bankruptcies Rebound from Pandemic Lull
A recent report offers new insight into bankruptcy trends within the sector starting before the COVID-19 pandemic.
Compliance Tool: Model Mandatory Excluded Provider Screening Policy
A written policy helps establish your right to do excluded persons checks and take appropriate actions if they come back positive.
Labs in Court
In recent key cases, the national drug retailer must stand trial for failing to protect customers from faulty Theranos products.
Billing & Coding: What to Know About New Category III CPT Codes for Digital Pathology
The new codes have garnered attention as a future mechanism for additional reimbursement and thus deserve further discussion.
Compliance Perspectives: How to Perform Excluded Provider Checks
Hiring, retaining, or simply doing business with the wrong people may expose your lab to significant financial penalties.
Expert Q&A: Trends in Precision Medicine
Christian Olsen, a leader in R&D scientific software, discusses recent developments related to AI and solutions to current precision medicine challenges.
